Let me start by outlining a few things we’re not doing.
We’re not another aggregation machine. There are plenty of places that will give you a quick and sterile snapshot of the biopharma R&D world. And that’s not us.
We’re not the AP or any other wire service. There’s already an AP, Reuters, Bloomberg, and they do a fine job. That job is covered.
We’re not stock pickers. Frankly, we wouldn’t know where to begin.
Many of you may know Publisher Arsalan Arif and I from an earlier company we worked at.
We’re not that company, either.
— John Carroll (@JohnCendpts) June 9, 2016
So what are we?
We’re a deeply experienced team of owner/editors that has spent more than a decade learning about global drug development and digital media. We aim to put that experience, and the contacts we’ve developed in-person and online to work for you; analyzing industry news for industry professionals, providing the data and information needed to intelligently assess where the biopharma research industry is headed.
Yes, in addition to breaking stories and plenty of entirely original content, we will also source pubs around the globe in pursuit of a big goal. But we will always put the news in context. And we will always cut to the chase. That’s our secret sauce. And it’s something that can’t be cloned.
Over the past two years, Arsalan has been developing a new digital news platform that employs its own original approach to highlighting the reports from around the globe that matter most. That’s our Early Edition, which he hammers away at during predawn hours. And he also has an entertaining/insightful collection of links to the most sought-after content, ranked by Twitter popularity.
You’ll find Arsalan and I again in our main edition at noon EST (pub time, London; Starbucks time, San Francisco; the midnight special in Shanghai), providing an analytical, data driven daily report on the drug R&D world. I’ll spend my day focused on interpreting the top news and providing a data-driven set of analytics specifically for biopharma professionals. Go to endpts.com to catch the live stream, as I pursue a real-time conversation with readers.
Online financial news hasn’t just created a new outlet for media. It’s fundamentally demanded a new style that requires a lot of hands-on experience.
That’s who we are.
It won’t all be 100% finished. We’ll probably never be 100% done with anything. The business we’re in is changing in explosive ways. We’ll try to keep up, sometimes we may try to lead.
If you’ve got questions, drop me a line. The best way to understand is to read one of our reports.
We hope you subscribe and stay with us for this ride. We’ll work for it.
— John Carroll email@example.com
— Adam Feuerstein (@adamfeuerstein) June 16, 2016
Big news! One of my fave writers joins up with my fave newsletter. https://t.co/1be4i4C9oD
— Matthew Herper (@matthewherper) June 9, 2016
— Jon Rees (@BiotechJon) June 17, 2016
@AKAarsalan I love the analogy of tamingthe biotech firehose to a manageable trickle.. One of my favorite writers and my favorite newsletter
— Ron Guido (@GUIDO_RGU) June 10, 2016
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription